Masayendisiti epaMichigan State University ari kugadzira utachiona hwakafanana nehutachiona hunodaidzwa kuti Qβ, hunoburitsa mhinduro yekurwisa kenza mumuviri uye inogona kushandiswa semushonga mutsva wekurapa cancer. Chirongwa cheUS $ 2.4 miriyoni chinotsigirwa neNational Cancer Institute chichatsigira kugadzirwa kwejekiseni rekudzivirira mhuka kubva kumaseru egomarara pari zvino, uye inogona kunge iri mushonga wegomarara rinongoerekana raitika muvanhu.
Chikwata ichi chinosanganisa Qβ zvidimbu zvine bundu-zvine hukama makabhohaidhiretsi maantigen (TACAs), uye ivo vanotenda aya maantigen anogadzira akazara anti-bundu maseru ekudzivirira, kudzora bundu kukura uye kudzivirira bundu kukura. Uye zvakare, ivo vaongorori vanoshandisa iyo yekristaro dhizaini yeQ mut kugadzira shanduko idzo dzinodzora hutachiona hutachiona nekusimudzira maseru anodikanwa, ayo anogona zvakare kuuraya maseru ekenza. Uku ndiko kuedza kwekutanga kwakadaro uchishandisa modhi yekudzivirira TACA.
This vaccine will be used first to treat canine cancer and will focus on osteosarcoma, which is a refractory dog and human bone tumarara.
Vaccines can reduce tumor growth and protect patients from tumor progression and further progress. If we can further understand the relationship between the structural characteristics of Qβ-TACA and anti-tumor immunity, it can have a great effect on the design of majekiseni egomarara. This research also strengthens the important role of veterinary medicine in cancer research.
Yuzbasiyan-Gurkan akati: “Kenza inongoerekana yaitika imbwa nekatsi inopa bvunzo chaiyo yezvirwere zvegomarara. "Uyu unongova mumwe wemienzaniso yenzira dzakawanda dzekutsvagisa kwemhuka uye kurapwa kwevanhu dzinogona kubatsirana."
